Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel Free NFX Stock Alerts

Nuformix (NFX) Competitors

Nuformix logo
GBX 0.17 0.00 (0.00%)
As of 06/5/2026 12:00 PM Eastern
Compare

NFX vs. IXI, APTA, FAB, RLM, and NSCI

Should you buy Nuformix stock or one of its competitors? MarketBeat compares Nuformix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Nuformix include IXICO (IXI), Aptamer Group (APTA), Fusion Antibodies (FAB), Realm Therapeutics (RLM), and NetScientific (NSCI). These companies are all part of the "biotechnology" industry.

How does Nuformix compare to IXICO?

Nuformix (LON:NFX) and IXICO (LON:IXI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, media sentiment, dividends, profitability and analyst recommendations.

In the previous week, IXICO had 1 more articles in the media than Nuformix. MarketBeat recorded 1 mentions for IXICO and 0 mentions for Nuformix. IXICO's average media sentiment score of 0.67 beat Nuformix's score of 0.00 indicating that IXICO is being referred to more favorably in the news media.

Company Overall Sentiment
Nuformix Neutral
IXICO Positive

Nuformix has higher earnings, but lower revenue than IXICO. Nuformix is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuformixN/AN/A-£383.40K-£0.03N/A
IXICO£7.28M2.49-£3.58M-£1.95N/A

Nuformix has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
NuformixN/A -83.53% -17.20%
IXICO -24.98%-16.18%-10.40%

0.1% of Nuformix shares are held by institutional investors. Comparatively, 13.0% of IXICO shares are held by institutional investors. 7.5% of Nuformix shares are held by insiders. Comparatively, 7.2% of IXICO shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Nuformix has a beta of 1.545, meaning that its stock price is 55% more volatile than the broader market. Comparatively, IXICO has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market.

Summary

IXICO beats Nuformix on 7 of the 12 factors compared between the two stocks.

How does Nuformix compare to Aptamer Group?

Aptamer Group (LON:APTA) and Nuformix (LON:NFX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Nuformix has lower revenue, but higher earnings than Aptamer Group. Nuformix is trading at a lower price-to-earnings ratio than Aptamer Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptamer Group£1.38M13.79-£14.17M-£0.11N/A
NuformixN/AN/A-£383.40K-£0.03N/A

In the previous week, Aptamer Group's average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company Overall Sentiment
Aptamer Group Neutral
Nuformix Neutral

3.0% of Aptamer Group shares are held by institutional investors. Comparatively, 0.1% of Nuformix shares are held by institutional investors. 7.3% of Aptamer Group shares are held by insiders. Comparatively, 7.5% of Nuformix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aptamer Group has a beta of 0.916, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Nuformix has a beta of 1.545, meaning that its stock price is 55% more volatile than the broader market.

Nuformix has a net margin of 0.00% compared to Aptamer Group's net margin of -178.52%. Nuformix's return on equity of -83.53% beat Aptamer Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Aptamer Group-178.52% -135.35% -44.96%
Nuformix N/A -83.53%-17.20%

Summary

Nuformix beats Aptamer Group on 7 of the 10 factors compared between the two stocks.

How does Nuformix compare to Fusion Antibodies?

Fusion Antibodies (LON:FAB) and Nuformix (LON:NFX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, profitability, earnings, institutional ownership and dividends.

Fusion Antibodies has a beta of 1.215, indicating that its share price is 22% more volatile than the broader market. Comparatively, Nuformix has a beta of 1.545, indicating that its share price is 55% more volatile than the broader market.

Nuformix has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Nuformix's return on equity of -83.53% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
Nuformix N/A -83.53%-17.20%

Nuformix has lower revenue, but higher earnings than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Nuformix, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M9.44-£4.10M-£1.50N/A
NuformixN/AN/A-£383.40K-£0.03N/A

In the previous week, Fusion Antibodies had 1 more articles in the media than Nuformix. MarketBeat recorded 1 mentions for Fusion Antibodies and 0 mentions for Nuformix. Fusion Antibodies' average media sentiment score of 1.11 beat Nuformix's score of 0.00 indicating that Fusion Antibodies is being referred to more favorably in the media.

Company Overall Sentiment
Fusion Antibodies Positive
Nuformix Neutral

7.6% of Fusion Antibodies shares are held by institutional investors. Comparatively, 0.1% of Nuformix shares are held by institutional investors. 5.9% of Fusion Antibodies shares are held by insiders. Comparatively, 7.5% of Nuformix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Nuformix beats Fusion Antibodies on 8 of the 12 factors compared between the two stocks.

How does Nuformix compare to Realm Therapeutics?

Nuformix (LON:NFX) and Realm Therapeutics (LON:RLM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Realm Therapeutics' return on equity of 0.00% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
NuformixN/A -83.53% -17.20%
Realm Therapeutics N/A N/A N/A

In the previous week, Nuformix's average media sentiment score of 0.00 equaled Realm Therapeutics'average media sentiment score.

Company Overall Sentiment
Nuformix Neutral
Realm Therapeutics Neutral

0.1% of Nuformix shares are held by institutional investors. 7.5% of Nuformix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Realm Therapeutics has higher revenue and earnings than Nuformix. Nuformix is trading at a lower price-to-earnings ratio than Realm Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NuformixN/AN/A-£383.40K-£0.03N/A
Realm Therapeutics£501.92K0.00N/A-£17.50N/A

Summary

Realm Therapeutics beats Nuformix on 4 of the 7 factors compared between the two stocks.

How does Nuformix compare to NetScientific?

NetScientific (LON:NSCI) and Nuformix (LON:NFX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

In the previous week, NetScientific's average media sentiment score of 0.00 equaled Nuformix'saverage media sentiment score.

Company Overall Sentiment
NetScientific Neutral
Nuformix Neutral

Nuformix has lower revenue, but higher earnings than NetScientific. Nuformix is trading at a lower price-to-earnings ratio than NetScientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NetScientific£1.45M0.00-£2.64M-£0.11N/A
NuformixN/AN/A-£383.40K-£0.03N/A

Nuformix has a net margin of 0.00% compared to NetScientific's net margin of -182.91%. NetScientific's return on equity of -13.70% beat Nuformix's return on equity.

Company Net Margins Return on Equity Return on Assets
NetScientific-182.91% -13.70% -9.42%
Nuformix N/A -83.53%-17.20%

NetScientific has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, Nuformix has a beta of 1.545, suggesting that its share price is 55% more volatile than the broader market.

14.7% of NetScientific shares are held by institutional investors. Comparatively, 0.1% of Nuformix shares are held by institutional investors. 42.4% of NetScientific shares are held by company insiders. Comparatively, 7.5% of Nuformix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

NetScientific beats Nuformix on 6 of the 10 factors compared between the two stocks.

Get Nuformix News Delivered to You Automatically

Sign up to receive the latest news and ratings for NFX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NFX vs. The Competition

Export
MetricNuformixBiotechnology IndustryMedical SectorLON Exchange
Market Cap£4.41M£460.10M£6.68B£2.75B
Dividend YieldN/A3.87%2.67%6.16%
P/E Ratio-5.773.1524.06366.37
Price / SalesN/A6,626.88516.1887,126.24
Price / Cash3.5513.1342.2327.85
Price / Book0.3183.479.737.68
Net Income-£383.40K-£96.07M£3.57B£5.89B
7 Day Performance-18.75%-2.00%-1.28%-0.50%
1 Month Performance-7.14%1.08%1.38%1.84%
1 Year Performance57.94%64.32%23.93%72.87%

Nuformix Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NFX
Nuformix
N/AGBX 0.17
flat		N/A+57.9%£4.41MN/AN/A3
IXI
IXICO
N/AGBX 8.30
-4.5%		N/A-26.4%£18.10M£7.28MN/A89
APTA
Aptamer Group
N/AGBX 0.50
-12.3%		N/A+58.0%£17.28M£1.38MN/A37
FAB
Fusion Antibodies
N/AGBX 12.07
-7.2%		N/A+74.6%£15.09M£1.60MN/A48
RLM
Realm Therapeutics
N/AN/AN/AN/A£13.41M£501.92KN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:NFX) was last updated on 6/7/2026 by MarketBeat.com Staff.
From Our Partners
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
June 12: $100 Turns Into $100,000?
The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...
Brownstone Research | Sponsoredtc pixel
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
SpaceX just filed. The clock is ticking.
Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...
The Oxford Club | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
SpaceX will mint billionaires. You won't be one of them.
By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...
Behind the Markets | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel